Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUASENSE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Schizophrenia,Bipolar I disorder (manic, mixed, depressive episodes),Major depressive disorder (adjunctive),Bipolar maintenance therapy
Prevention of pregnancy (FDA-approved)
100 mg orally every 12 hours.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is 8–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (Cr Cl <30 m L/min), requiring dose adjustment.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Primarily hepatic via CYP3A4; also CYP2D6 and CYP2C9. Metabolite N-desalkylquetiapine (norquetiapine) is active.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily renal excretion (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for about 20% (including metabolites); 10% undergoes metabolic clearance.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
92–96% bound primarily to serum albumin; also binds to alpha-1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
0.8–1.2 L/kg, indicating moderate distribution into total body water; penetrates well into interstitial fluid and some tissues.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 75–90% (due to moderate first-pass metabolism; absorption is rapid and complete).
Oral: ~70% due to first-pass metabolism.
GFR 30-50: 100 mg every 24 hours; GFR 15-29: 100 mg every 48 hours; GFR <15: not recommended.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh A: no dose adjustment; Child-Pugh B: 50 mg every 12 hours; Child-Pugh C: not recommended.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
For children aged 6-12 years: 1 mg/kg/dose (max 50 mg) every 12 hours; ages 12-18: same as adult.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Starting dose 50 mg every 12 hours; titrate based on renal function and tolerability.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Increased risk of death in elderly patients with dementia-related psychosis. Antidepressants increased risk of suicidal thinking and behavior in children, adolescents, and young adults.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Neuroleptic Malignant Syndrome,Tardive dyskinesia,Metabolic changes: hyperglycemia/diabetes, dyslipidemia, weight gain,Leukopenia/neutropenia,Seizures,Hypotension/orthostatic hypotension,Cataracts,QT prolongation
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hypersensitivity to quetiapine or any excipients
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid grapefruit juice as it may increase estrogen levels. No other significant food interactions. Take with food if gastrointestinal upset occurs.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
QUASENSE (desogestrel/ethinyl estradiol) is pregnancy category X. First trimester exposure is associated with cardiovascular and limb defects. Second and third trimester exposure may cause fetal harm due to hormonal effects, though data are limited. Contraindicated in pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and desogestrel are excreted in breast milk. M/P ratio not established. May reduce milk production and composition. Use is generally not recommended during breastfeeding.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended as use is avoided.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Quasense is a combination oral contraceptive with ethinyl estradiol and levonorgestrel. It has a 91-day extended cycle (84 active pills, 7 placebo). Prescribe for women with endometriosis or menstrual-related disorders to reduce frequency of withdrawal bleeds. Counsel that spotting/breakthrough bleeding is common in first few cycles. Contraindicated in women with history of thromboembolic events, migraine with aura, or age >35 who smoke. Monitor blood pressure and liver function. Acetaminophen and other CYP3A4 inducers may reduce efficacy; consider additional contraception during coadministration.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time; missed pills increase pregnancy risk.,Expect irregular bleeding or spotting, especially during the first 3-6 months.,Use backup contraception (e.g., condoms) if you miss pills or start a new medication that may interfere.,Do not smoke while taking this medication; smoking increases risk of blood clots and stroke.,Seek emergency care for signs of blood clot (leg pain/swelling, chest pain, sudden severe headache or vision changes).
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUASENSE vs AFIRMELLE, answered by our medical review team.
QUASENSE is a Oral Contraceptive that works by Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUASENSE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUASENSE is: 100 mg orally every 12 hours.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUASENSE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUASENSE is classified as Category C. QUASENSE (desogestrel/ethinyl estradiol) is pregnancy category X. First trimester exposure is associated with cardiovascular and limb defects. Second and third trimester exposure m. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.